Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wanling Xie

Showing results (1-10 of 149) with videos related to

Pageof 15
Sort By:
European Urology|July 26, 2018
Eighteen Months of Androgen Deprivation Therapy in Men with High-risk Prostate Cancer and the Risk of DeathWanling Xie, Anthony V D'Amico
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2017
Reply to Y. Zhu et alWanling Xie, Meredith M Regan, Christopher J Sweeney
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2021
Reply to G. Francolini et alAnthony V D'Amico, Wanling Xie, Philip W Kantoff
Cancer|October 26, 2007
Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphataseWanling Xie, Mari Nakabayashi, Meredith M Regan, et al.
Clinical, Cosmetic and Investigational Dermatology|May 13, 2026
Repair of Areolar Defect Following the Excision of Sebaceous Cyst by Applying Kite-Flap: A Case Report and Literature ReviewNanyuan Jiang, Jiachen Xu, Wanling Xie, et al.
Work and Occupations|June 11, 2008
TRACING THE TIMING OF "CAREER" ACQUISITION IN A CONTEMPORARY YOUTH COHORTJeylan T Mortimer, Mike Vuolo, Jeremy Staff, et al.
Cancer Journal (Sudbury, Mass.)|May 4, 2007
Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancerMari Nakabayashi, Jonathan Ling, Wanling Xie, et al.
Research Square|March 18, 2024
Discover overlooked complications after preeclampsia using electronic health recordsLana Garmire, Haoming Zhu, Xiaotong Yangs, et al.
European Urology|January 3, 2017
Reply to Roberto Iacovelli, Walter Artibani, and Giampaolo Tortora's Letter to the Editor re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970-8Ian D Davis, Carmel Pezaro, Wanling Xie, et al.
Cancer|July 25, 2006
Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancerMari Nakabayashi, Wanling Xie, Meredith M Regan, et al.
Pageof 15

Showing results (1-10 of 149) with videos related to

Sort By:
Pageof 15
European Urology|July 26, 2018
Eighteen Months of Androgen Deprivation Therapy in Men with High-risk Prostate Cancer and the Risk of DeathWanling Xie, Anthony V D'Amico
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2017
Reply to Y. Zhu et alWanling Xie, Meredith M Regan, Christopher J Sweeney
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2021
Reply to G. Francolini et alAnthony V D'Amico, Wanling Xie, Philip W Kantoff
Cancer|October 26, 2007
Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphataseWanling Xie, Mari Nakabayashi, Meredith M Regan, et al.
Clinical, Cosmetic and Investigational Dermatology|May 13, 2026
Repair of Areolar Defect Following the Excision of Sebaceous Cyst by Applying Kite-Flap: A Case Report and Literature ReviewNanyuan Jiang, Jiachen Xu, Wanling Xie, et al.
Work and Occupations|June 11, 2008
TRACING THE TIMING OF "CAREER" ACQUISITION IN A CONTEMPORARY YOUTH COHORTJeylan T Mortimer, Mike Vuolo, Jeremy Staff, et al.
Cancer Journal (Sudbury, Mass.)|May 4, 2007
Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancerMari Nakabayashi, Jonathan Ling, Wanling Xie, et al.
Research Square|March 18, 2024
Discover overlooked complications after preeclampsia using electronic health recordsLana Garmire, Haoming Zhu, Xiaotong Yangs, et al.
European Urology|January 3, 2017
Reply to Roberto Iacovelli, Walter Artibani, and Giampaolo Tortora's Letter to the Editor re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970-8Ian D Davis, Carmel Pezaro, Wanling Xie, et al.
Cancer|July 25, 2006
Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancerMari Nakabayashi, Wanling Xie, Meredith M Regan, et al.
Pageof 15